Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.01M | $15.1M | $49.9M | $103M | $115M | $130M | $114M | $119M |
| Revenue growth | — | 651.3% | 231.2% | 105.5% | 12.4% | 13.0% | -12.8% | 5.1% |
| Gross profit | -$6.12M | -$17.8M | -$13.0M | $7.61M | $17.8M | $29.0M | $38.6M | $46.8M |
| Gross margin | -304.7% | -118.1% | -26.1% | 7.4% | 15.5% | 22.2% | 33.9% | 39.1% |
| Operating income | -$46.6M | -$70.3M | -$117M | -$131M | -$161M | -$170M | -$113M | -$66.7M |
| Operating margin | -2320.0% | -466.3% | -235.2% | -127.2% | -139.6% | -130.2% | -99.7% | -55.8% |
| Net income | -$49.8M | -$68.3M | -$121M | -$132M | -$163M | -$173M | -$128M | -$81.7M |
| Net margin | -2480.3% | -453.0% | -243.3% | -128.6% | -141.2% | -132.5% | -112.6% | -68.3% |
| EPS (diluted) | -$100.75 | -$99.58 | -$4.85 | -$2.89 | -$3.38 | -$52.28 | -$36.96 | -$5.37 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$46.4M | -$70.3M | -$99.0M | -$130M | -$146M | -$131M | -$116M | -$46.3M |
| Capital expenditures | $1.77M | $3.29M | $9.08M | $3.11M | $8.32M | $3.44M | $912K | $798K |
| Free cash flow | -$48.2M | -$73.6M | -$108M | -$133M | -$154M | -$135M | -$117M | -$47.1M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $36.9M | $295M | $182M | $73.2M | $68.5M | $124M | $35.0M |
| Total assets | — | $88.4M | $404M | $463M | $400M | $314M | $276M | $264M |
| Total liabilities | — | $51.1M | $75.2M | $89.4M | $154M | $191M | $249M | $138M |
| Long-term debt | — | $21.6M | $29.7M | $29.8M | $96.3M | $130M | $197M | $96.2M |
| Shareholders' equity | -$288M | -$372M | $329M | $374M | $246M | $123M | $26.8M | $127M |
| Retained earnings | — | -$373M | -$494M | -$626M | -$789M | -$962M | -$1.09B | -$1.17B |
| Shares (wtd avg diluted) | — | 922K | 16.4B | 45.6B | 48.2B | 3.31B | 3.46B | 15.2B |
Every figure is extracted from Outset Medical, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.